Skip to main content
Investors
Media
open in a new window
Contact Us
open in a new window
|
Search
open in a new window
Company
Science & Medicine
Patients
Responsibility
Careers
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Annual Meeting
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Stock Information
Stock Quote & Chart
Historical Stock Quote
Analyst Coverage
Investor FAQs
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Annual Meeting
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Stock Information
Stock Quote & Chart
Historical Stock Quote
Analyst Coverage
Investor FAQs
Close
Close
Investors
Company
Product
Research & Development
Patients
Partnerships
Careers
Close
Press Releases
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
August 8, 2023
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
July 25, 2023
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
June 29, 2023
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
June 16, 2023
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
June 12, 2023
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
May 22, 2023
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
May 9, 2023
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 8, 2023
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
May 4, 2023
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
April 24, 2023
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
April 20, 2023
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
February 27, 2023
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
February 16, 2023
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
February 13, 2023
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
February 2, 2023
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
January 9, 2023
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
January 4, 2023
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference